2024年1月至10月芬兰持续流行期间发现的耐大环内酯百日咳博德泰拉菌株。

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2024-12-01 DOI:10.2807/1560-7917.ES.2024.29.49.2400765

Milja Miettinen, Alex-Mikael Barkoff, Aino Nyqvist, Carita Savolainen-Kopra, Jenni Antikainen, Jussi Mertsola, Lauri Ivaska, Qiushui He

{"title":"2024年1月至10月芬兰持续流行期间发现的耐大环内酯百日咳博德泰拉菌株。","authors":"Milja Miettinen, Alex-Mikael Barkoff, Aino Nyqvist, Carita Savolainen-Kopra, Jenni Antikainen, Jussi Mertsola, Lauri Ivaska, Qiushui He","doi":"10.2807/1560-7917.ES.2024.29.49.2400765","DOIUrl":null,"url":null,"abstract":"Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin > 256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 49","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650481/pdf/","citationCount":"0","resultStr":"{\"title\":\"Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024.\",\"authors\":\"Milja Miettinen, Alex-Mikael Barkoff, Aino Nyqvist, Carita Savolainen-Kopra, Jenni Antikainen, Jussi Mertsola, Lauri Ivaska, Qiushui He\",\"doi\":\"10.2807/1560-7917.ES.2024.29.49.2400765\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin > 256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"29 49\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650481/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2024.29.49.2400765\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2024.29.49.2400765","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

自2024年4月以来，芬兰一直在流行百日咳，截至10月底报告了2,215例病例。其中30.1% （n = 667）年龄在10 ~ 14 岁之间。462株百日咳博德泰菌中1株对大环内酯耐药（红霉素、阿奇霉素和克拉霉素的最低抑菌浓度为256 μg/mL）。耐药分离株血清型为FIM2，疫苗抗原peractn缺失，携带ptxP3等位基因。大环内酯耐药百日咳在欧洲的出现令人担忧，其快速识别是重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024.

Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin > 256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.